Drug class
Topical photosensitiser; prodrug for photodynamic therapy
Mechanism of action
Methyl aminolevulinate is converted intracellularly to photoactive porphyrins, including protoporphyrin IX, which accumulate in treated skin lesions. After illumination with light of an appropriate wavelength in the presence of oxygen, these porphyrins generate singlet oxygen and other reactive oxygen species, causing phototoxic damage to target cells.
General use cases
- Photodynamic treatment of actinic keratoses.
- Photodynamic treatment of selected superficial basal cell carcinomas and Bowen’s disease, according to the authorised product label and illumination protocol.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
